See ThruEquity has a $0.64 USD Target on MPHMF Excellent research report. www.baystreet.ca/articles/research_reports/SeeThruEquity/a15970_951f2ac651a74acd87ce77a527ebb434.pdf
FDA Confirmed Faster Pathway to Market Approval for C-103 M Pharmaceutical Inc. pursuing 505 (b) (2) pathway for C-103: M Pharma's reformulated version of Orlistat (C-103) is designed to maintain the safety and efficacy benefits of Orlistat while minimizing / eliminating the uncomfortable and embarrassing side effects. As part of the transaction, M Pharma has acquired issued US patents covering C-103 technology until 2030 from Chelatexx. The FDA confirmed C-103 is eligible for 505 (b) (2) in the US, which is significant because the 505 (b) (2) regulatory pathway should allow M Pharma to rely in part on Orlistat data, which could speed time to market. M Pharma estimates peak sales potential for C-103 of $200 million + annually.
